Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lu-PRRT Used More Intensively on Advanced Gastro-Entero-Pancreatic and Lung Neuroendocrine Neoplasms: Preliminary Results on Toxicity from a Randomized Study.
Grassi I, Nicolini S, Marini I, Matteucci F, Ranallo N, Di Iorio V, Sarnelli A, Foca F, Monti M, Fabbri L, Fantini L, Rossi A, Paganelli G, Severi S, Sansovini M. Grassi I, et al. Among authors: foca f. Neuroendocrinology. 2024 Nov 21:1-12. doi: 10.1159/000542328. Online ahead of print. Neuroendocrinology. 2024. PMID: 39571544 Free article.
First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax).
Ridolfi L, Gurrieri L, Riva N, Bulgarelli J, De Rosa F, Guidoboni M, Fausti V, Ranallo N, Calpona S, Tazzari M, Petrini M, Granato AM, Pancisi E, Foca F, Dall'Agata M, Bondi I, Amadori E, Cortesi P, Zani C, Ancarani V, Gamboni A, Polselli A, Pasini G, Bartolini D, Maimone G, Arpa D, Tosatto L. Ridolfi L, et al. Among authors: foca f. Front Immunol. 2024 Aug 13;15:1404861. doi: 10.3389/fimmu.2024.1404861. eCollection 2024. Front Immunol. 2024. PMID: 39192978 Free PMC article. Clinical Trial.
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.
Bongiovanni A, Liverani C, Foca F, Bergamo F, Leo S, Pusceddu S, Gelsomino F, Brizzi MP, Di Meglio G, Spada F, Tamberi S, Lolli I, Cives M, Marconcini R, Pucci F, Berardi R, Antonuzzo L, Badalamenti G, Santini D, Recine F, Vanni S, Tebaldi M, Severi S, Rudnas B, Nanni O, Ranallo N, Crudi L, Calabrò L, Ibrahim T. Bongiovanni A, et al. Among authors: foca f. Eur J Cancer. 2024 Sep;208:114129. doi: 10.1016/j.ejca.2024.114129. Epub 2024 May 25. Eur J Cancer. 2024. PMID: 39002347 Free article. Clinical Trial.
Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("PEMBROREAL" Study).
Cafaro A, Foca F, Nanni O, Chiumente M, Coppola M, Russi A, Svegliati E, Baldo P, Orzetti S, Enrico F, Foglio F, Pinnavaia D, Ladisa V, Lauria Pantano C, Lerose R, Nardulli P, Ferraiuolo S, Maiolino P, De Stasio I, Gradellini F, Gasbarro AR, Santeramo R, Carrucciu G, Provasi R, Cirino M, Cappelletto PC, Fonzi E, Pasqualini A, Vecchia S, Veraldi M, De Francesco AE, Crinò L, Delmonte A, Masini C. Cafaro A, et al. Among authors: foca f. Cancers (Basel). 2024 May 8;16(10):1802. doi: 10.3390/cancers16101802. Cancers (Basel). 2024. PMID: 38791882 Free PMC article.
A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL).
Cafaro A, Foca F, Nanni O, Chiumente M, Coppola M, Baldo P, Orzetti S, Enrico F, Ladisa V, Lerose R, Nardulli P, Maiolino P, Gradellini F, Gasbarro AR, Carrucciu G, Provasi R, Cappelletto PC, Pasqualini A, Vecchia S, Veraldi M, De Francesco AE, Crinò L, Delmonte A, Masini C. Cafaro A, et al. Among authors: foca f. Front Oncol. 2024 Mar 27;14:1351995. doi: 10.3389/fonc.2024.1351995. eCollection 2024. Front Oncol. 2024. PMID: 38601759 Free PMC article.
Radiotherapy at the End of Life: From Retrospective Analysis to Strategies to Improve Outcomes.
Rossi R, Cravero P, Pallotti MC, Valenti V, Massa I, Foca F, Nanni O, Pieri M, Romeo A, Tontini L, Donati CM, Morganti AG, Maltoni M. Rossi R, et al. Among authors: foca f. J Pain Symptom Manage. 2024 Jun;67(6):e927-e929. doi: 10.1016/j.jpainsymman.2024.03.001. Epub 2024 Mar 10. J Pain Symptom Manage. 2024. PMID: 38467347 No abstract available.
A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors.
Medri M, Savoia F, Foca F, Miserocchi A, Quaglino P, Rubatto M, Gullo G, Nardini C, Panasiti V, DE Tursi M, DI Marino P, Brancaccio G, Giunta EF, Napolitano S, Cinotti E, Brusasco M, Stanganelli I; IMI, Italian Melanoma Intergroup. Medri M, et al. Among authors: foca f. Ital J Dermatol Venerol. 2023 Dec;158(6):437-444. doi: 10.23736/S2784-8671.23.07542-4. Ital J Dermatol Venerol. 2023. PMID: 38015482 Free article.
Predisposition to eating disorders in adults with type 1 diabetes: Comparison between multiple daily injections and continuous subcutaneous insulin infusion.
Policola C, Di Stasio E, Rizzi A, Focà F, Tartaglione L, Locantore P, Ramunno V, Leo ML, Chieffo DPR, Rinaldi L, Della Casa S, Pontecorvi A, Pitocco D. Policola C, et al. Among authors: foca f. Diabetes Res Clin Pract. 2023 Sep;203:110882. doi: 10.1016/j.diabres.2023.110882. Epub 2023 Aug 16. Diabetes Res Clin Pract. 2023. PMID: 37595845
107 results